ArticleScientific reports2021
The fecal mycobiome in patients with Irritable Bowel Syndrome.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Visualization analysis of research hotspots and trends in traditional Chinese medicine external therapies for irritable bowel syndrome.Frontiers in medicine · 2026Pooled it
- Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis.The American journal of clinical nutrition · 2022Pooled it
- Machine learning-based assessment of the healthy human gut mycobiota landscape using ITS1 DNA metabarcoding data.BioData mining · 2026Article
- Yeasts in the gastrointestinal tract.FEMS yeast research · 2026Review
- The pathogenicity and future treatment strategies ofFrontiers in cellular and infection microbiology · 2026Review
- Bacterial-Fungal Interactions: Mutualism, Antagonism, and Competition.Life (Basel, Switzerland) · 2025Review
- Gut microbiota in irritable bowel syndrome: a narrative review of mechanisms and microbiome-based therapies.Frontiers in immunology · 2025Review
- A preliminary study of the association betweenFrontiers in medicine · 2025Article
- Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.Nutrients · 2024Review
- Article
- Fungal Microbiota Composition in Inflammatory Bowel Disease Patients: Characterization in Different Phenotypes and Correlation With Clinical Activity and Disease Course.Inflammatory bowel diseases · 2024Article
- Dysregulated brain-gut axis in the setting of traumatic brain injury: review of mechanisms and anti-inflammatory pharmacotherapies.Journal of neuroinflammation · 2024Review
- Gut mycobiome dysbiosis after sepsis and trauma.Critical care (London, England) · 2024Article
- Infant diarrheal disease in rhesus macaques impedes microbiome maturation and is linked to uncultured Campylobacter species.Communications biology · 2024Article
- Candida spp. in Human Intestinal Health and Disease: More than a Gut Feeling.Mycopathologia · 2023Review
- Effect of Different Feeds on the Fungi Microbiome of Suffolk Crossed with Tibetan Sheep.Life (Basel, Switzerland) · 2023Article
- Development of gut mycobiome in infants and young children: a prospective cohort study.Pediatric research · 2023Article
- Host Factors Associated with Gut Mycobiome Structure.mSystems · 2023Article
- The Role of Yeasts in Human Health: A Review.Life (Basel, Switzerland) · 2023Review
- Irritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations of the gut microbiota have been reported in various gastrointestinal disorders, but knowledge of the mycobiome is limited. We investigated the gut mycobiome of 80 patients with Irritable Bowel Syndrome (IBS) in comparison with 64 control subjects. The fungal-specific internal transcribed spacer 1 (ITS-1) amplicon was sequenced, and mycobiome zero-radius operational taxonomic units (zOTUs) were defined representing known and unknown species and strains. The fungal community was sparse and individual-specific in all (both IBS and control) subjects. Although beta-diversity differed significantly between IBS and controls, no difference was found among clinical subtypes of IBS or in comparison with the mycobiome of subjects with bile acid malabsorption (BAM), a condition which may overlap with IBS with diarrhoea. The mycobiome alterations co-varied significantly with the bacteriome and metabolome but were not linked with dietary habits. As a putative biomarker of IBS, the predictive power of the fecal mycobiome in machine learning models was significantly better than random but insufficient for clinical diagnosis. The mycobiome presents limited therapeutic and diagnostic potential for IBS, despite co-variation with bacterial components which do offer such potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.